Top

Published in:

Open Access 01-05-2010 | Perspectives

Testing the theory of immune selection in cancers that break the rules of transplantation

Authors: Ariberto Fassati, N. Avrion Mitchison

Published in: Cancer Immunology, Immunotherapy | Issue 5/2010

Abstract

Modification of cancer cells likely to reduce their immunogenicity, including loss or down-regulation of MHC molecules, is now well documented and has become the main support for the concept of immune surveillance. The evidence that these modifications, in fact, result from selection by the immune system is less clear, since the possibility that they may result from reorganized metabolism associated with proliferation or from cell de-differentiation remains. Here, we (a) survey old and new transplantation experiments that test the possibility of selection and (b) survey how transmissible tumours of dogs and Tasmanian devils provide naturally evolved tests of immune surveillance.

Mitchison N (1956) Antigens of heterozygous tumours as materials for the study of cell heredity. Proc Roy Phys Soc 25:45–48

Klein E, Klein G, Revesz L (1957) Permanent modification (mutation?) of a histocompatibility gene in a heterozygous tumor. J Natl Cancer Inst 19:95–114PubMed

Koebel CM et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907CrossRefPubMed

Murgia C et al (2006) Clonal origin and evolution of a transmissible cancer. Cell 126:477–487CrossRefPubMed

Thornley M (2004) Devils advocates Tasmanian. Devil facial tumor project. Aust Vet J 82:584CrossRefPubMed

Siddle HV et al (2007) Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci USA 104:16221–16226CrossRefPubMed

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148CrossRefPubMed

Cabrera T et al (2007) HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 56:709–717CrossRefPubMed

Choudhury SR, Knapp LA (2001) Human reproductive failure II: immunogenetic and interacting factors. Hum Reprod Update 7:135–160CrossRefPubMed

10.

Tian L, Catt JW, O’Neill C, King NJ (1997) Expression of immunoglobulin superfamily cell adhesion molecules on murine embryonic stem cells. Biol Reprod 57:561–568CrossRefPubMed

11.

Hori J et al (2003) Neural progenitor cells lack immunogenicity and resist destruction as allografts. Stem Cells 21:405–416CrossRefPubMed

12.

Mammolenti M, Gajavelli S, Tsoulfas P, Levy R (2004) Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro. Stem Cells 22:1101–1110CrossRefPubMed

13.

Snell GD (1953) The genetics of transplantation. J Natl Cancer Inst 14:691–700 (discussion 701–4)PubMed

14.

Jimenez P et al (1999) Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 83:91–97CrossRefPubMed

15.

Yauk CL, Bois PR, Jeffreys AJ (2003) High-resolution sperm typing of meiotic recombination in the mouse MHC Ebeta gene. EMBO J 22:1389–1397CrossRefPubMed

16.

Garcia-Lora A et al (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106:521–527CrossRefPubMed

17.

Novinski M (1876) Zur Frage uber die impfung der krebsigen geschwulste. Zentralb Med Wissensch 14:790–791

18.

Cohen D (1985) The canine transmissible venereal tumor: a unique result of tumor progression. Adv Cancer Res 43:75–112CrossRefPubMed

19.

Rebbeck CA et al (2009) Origins and evolution of a transmissible cancer. Evolution 63:2340–2349CrossRefPubMed

20.

Cohen D (1973) The biological behaviour of the transmissible venereal tumour in immunosuppressed dogs. Eur J Cancer 9:253–258PubMed

21.

Perez J, Day MJ, Mozos E (1998) Immunohistochemical study of the local inflammatory infiltrate in spontaneous canine transmissible venereal tumour at different stages of growth. Vet Immunol Immunopathol 64:133–147CrossRefPubMed

22.

Gonzalez CM et al (2000) Canine transmissible venereal tumour: a morphological and immunohistochemical study of 11 tumours in growth phase and during regression after chemotherapy. J Comp Pathol 122:241–248CrossRefPubMed

23.

McCallum H (2008) Tasmanian devil facial tumour disease: lessons for conservation biology. Trends Ecol Evol 23:631–637CrossRefPubMed

24.

Pearse AM, Swift K (2006) Allograft theory: transmission of devil facial-tumour disease. Nature 439:549CrossRefPubMed

25.

Siddle HV, Sanderson C, Belov K (2007) Characterization of major histocompatibility complex class I and class II genes from the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 59:753–760CrossRefPubMed

26.

Akagi T et al (2009) Chromosomal abnormalities and novel disease-related regions in progression from Barrett’s esophagus to esophageal adenocarcinoma. Int J Cancer 125:2349–2359CrossRefPubMed

27.

Rodriguez T et al (2005) High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol Immunother 54:141–148CrossRefPubMed

28.

Mendez R et al (2008) Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother 57:719–729CrossRefPubMed

29.

Masuda K et al (2007) Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci 98:102–108CrossRefPubMed

30.

Isoda T et al (2009) Immunologically silent cancer clone transmission from mother to offspring. Proc Natl Acad Sci USA 106:17882–17885CrossRefPubMed

31.

Bleakley M, Lau L, Shaw PJ, Kaufman A (2002) Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant 29:843–852CrossRefPubMed

32.

Vago L et al (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 361:478–488CrossRefPubMed

33.

Cohen D, Shalev A, Krup M (1984) Lack of beta 2-microglobulin on the surface of canine transmissible venereal tumor cells. J Natl Cancer Inst 72:395–401PubMed

34.

Yang TJ, Chandler JP, Dunne-Anway S (1987) Growth stage dependent expression of MHC antigens on the canine transmissible venereal sarcoma. Br J Cancer 55:131–134PubMed

35.

Yang TJ (1988) Immunobiology of a spontaneously regressive tumor, the canine transmissible venereal sarcoma (review). Anticancer Res 8:93–95PubMed

36.

Gerloni M, Zanetti M (2005) CD4 T cells in tumor immunity. Springer Semin Immunopathol 27:37–48CrossRefPubMed

37.

Depontieu FR et al (2009) Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci USA 106:12073–12078PubMed

38.

Cohen D (1972) Detection of humoral antibody to the transmissible venereal tumour of the dog. Int J Cancer 10:207–212CrossRefPubMed

39.

Reith W, Mach B (2001) The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19:331–373CrossRefPubMed

40.

Muller-Hilke B, Mitchison NA (2006) The role of HLA promoters in autoimmunity. Curr Pharm Des 12:3743–3752CrossRefPubMed

41.

Mitchison NA, Mayer W (2007) A survey of H2 gene sequences, including new wild-derived genes. Int J Immunogenet 34:3–12CrossRefPubMed

42.

Wright KL, Ting JP (2006) Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 27:405–412CrossRefPubMed

43.

Chang YC et al (2008) Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 111:5054–5063CrossRefPubMed

44.

Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27:5869–5885CrossRefPubMed

45.

Setiadi AF et al (2008) Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 68:9601–9607CrossRefPubMed

46.

Yip L et al (2009) Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 10:1026–1033CrossRefPubMed

47.

Malmberg KJ et al (2008) NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother 57:1541–1552CrossRefPubMed

48.

Ambrosino E, Berzofsky JA, Terabe M (2008) Regulation of tumor immunity: the role of NKT cells. Expert Opin Biol Ther 8:725–734CrossRefPubMed

49.

Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N (2008) HLA-G: from biology to clinical benefits. Trends Immunol 29:125–132CrossRefPubMed

50.

Lin CY et al (2008) Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett 272:285–295CrossRefPubMed

51.

Kang SM, Tang Q, Bluestone JA (2007) CD4+ CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 7:1457–1463CrossRefPubMed

52.

Scheffold A, Huhn J, Hofer T (2005) Regulation of CD4+ CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol 35:1336–1341CrossRefPubMed

53.

Mozos E et al (1996) Immunohistochemical characterization of canine transmissible venereal tumor. Vet Pathol 33:257–263PubMedCrossRef

54.

Marchal T et al (1997) Immunophenotype of the canine transmissible venereal tumour. Vet Immunol Immunopathol 57:1–11CrossRefPubMed

55.

Hsiao YW, Liao KW, Hung SW, Chu RM (2004) Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol 172:1508–1514PubMed

56.

Dunn GP et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998CrossRefPubMed

57.

Chou PC et al (2009) Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles. Vet Immunol Immunopathol 130:25–34CrossRefPubMed

58.

Scherer MN et al (2007) Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg 392:511–523CrossRefPubMed

59.

Geissler EK, Schlitt HJ (2009) Immunosuppression for liver transplantation. Gut 58:452–463CrossRefPubMed

60.

Uppaluri R, Dunn GP, Lewis JS Jr (2008) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 8:16PubMed

61.

Milne K et al (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4:e6412CrossRefPubMed

62.

Galon J et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRefPubMed

63.

Pierobon M et al (2009) Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 8:110–117CrossRef

64.

Hsiao YW, Liao KW, Hung SW, Chu RM (2002) Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol 87:19–27CrossRefPubMed

65.

Willimsky G, Blankenstein T (2005) Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141–146CrossRefPubMed

66.

Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138:822–829CrossRefPubMed

67.

Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227–236CrossRefPubMed

68.

Mendez R et al (2009) HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother 58:1507–1515CrossRefPubMed

69.

Mehling M et al (2007) WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol 114:111–119CrossRefPubMed

70.

Carosella ED, HoWangYin KY, Favier B, LeMaoult J (2008) HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. Hum Immunol 69:700–707CrossRefPubMed

71.

Kretschmer K, Apostolou I, Verginis P, von Boehmer H (2008) Regulatory T cells and antigen-specific tolerance. Chem Immunol Allergy 94:8–15CrossRefPubMed

72.

Comin-Anduix B et al (2008) Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 6:22CrossRefPubMed

73.

Kavanagh B et al (2008) CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112:1175–1183CrossRefPubMed

74.

Kryczek I et al (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141–1149CrossRefPubMed

75.

Verheyden S et al (2009) Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol Immunother 58:855–865CrossRefPubMed

76.

Schwinn N et al (2009) Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 124:1594–1604CrossRefPubMed

77.

Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357–368CrossRefPubMed

78.

Moutsopoulos NM, Wen J, Wahl SM (2008) TGF-beta and tumors—an ill-fated alliance. Curr Opin Immunol 20:234–240CrossRefPubMed

79.

Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848CrossRefPubMed

80.

Lob S, Konigsrainer A (2008) Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg 393:995–1003CrossRefPubMed

81.

Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95–109CrossRefPubMed

82.

Wajant H (2006) CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res 130:141–165CrossRefPubMed

83.

Zhou J et al (2009) Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113:4052–4062CrossRefPubMed

Title: Testing the theory of immune selection in cancers that break the rules of transplantation
Authors: Ariberto Fassati
N. Avrion Mitchison
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 5/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0809-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting

Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidine

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy

A persistent virus vector confers superior anti-tumor immunity, compared with a non-persistent vector

Keynote webinar | Spotlight on antibody–drug conjugates in cancer